THE TALK: Gastrointestinal Cancers A Review of Data from the ESMO 2021 Virtual Meeting - Episode 1

ESMO 2021 Updates in Metastatic Esophageal Squamous Cell Carcinoma

November 15, 2021

Sam Klempner, MD, Massachusetts General Hospital , Daniel H. Ahn, DO, Mayo Clinic, Nataliya V. Uboha, MD, PhD, University of Wisconsin Carbone Cancer Center, Manish A. Shah, MD, FASCO, Weill Cornell Medicine/New York-Presbyterian Hospital

Experts in gastrointestinal cancers review recent updates and clinical implications from phase 3 trials presented at ESMO 2021 in metastatic esophageal squamous cell carcinoma (ESCC).

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

Now Viewing

EP. 1: ESMO 2021 Updates in Metastatic Esophageal Squamous Cell Carcinoma

EP. 2: ESMO 2021 Updates in Gastroesophageal and Gastric Adenocarcinomas

EP. 3: ESMO 2021 Updates in HER2+ Metastatic Gastric and Gastroesophageal Cancer

EP. 4: ESMO 2021 Updates in Gastric Cancer and Colorectal Cancer

Data from the following clinical trials are discussed:

1373M0 - JUPITER-06: A randomized, double-blind, phase 3 study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC) (JUPITER-06)
LBA52 - Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase 3 ORIENT-15 study (ORIENT-15)